SGLT2i = sodium-glucose cotransporter-2 inhibitor; GLP-1RA = glucagon-like peptide-1 receptor agonist; MACE = major adverse cardiovascular events (CV death, non-fatal MI, non-fatal stroke); HHF = hospitalization for heart failure; CV = cardiovascular; HF = heart failure; ACS = acute coronary syndrome; eGFR = estimated glomerular filtration rate; HbA1c = glycated hemoglobin; QW = once weekly; SC = subcutaneous. Here, SLC5A2 is linked to stroke disorder.